217 related articles for article (PubMed ID: 27270322)
21. A novel defined programmed cell death related gene signature for predicting the prognosis of serous ovarian cancer.
Zhan F; Guo Y; He L
J Ovarian Res; 2024 Apr; 17(1):92. PubMed ID: 38685095
[TBL] [Abstract][Full Text] [Related]
22. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
23. ABCA transporter gene expression and poor outcome in epithelial ovarian cancer.
Hedditch EL; Gao B; Russell AJ; Lu Y; Emmanuel C; Beesley J; Johnatty SE; Chen X; Harnett P; George J; ; Williams RT; Flemming C; Lambrechts D; Despierre E; Lambrechts S; Vergote I; Karlan B; Lester J; Orsulic S; Walsh C; Fasching P; Beckmann MW; Ekici AB; Hein A; Matsuo K; Hosono S; Nakanishi T; Yatabe Y; Pejovic T; Bean Y; Heitz F; Harter P; du Bois A; Schwaab I; Hogdall E; Kjaer SK; Jensen A; Hogdall C; Lundvall L; Engelholm SA; Brown B; Flanagan J; Metcalf MD; Siddiqui N; Sellers T; Fridley B; Cunningham J; Schildkraut J; Iversen E; Weber RP; Berchuck A; Goode E; Bowtell DD; Chenevix-Trench G; deFazio A; Norris MD; MacGregor S; Haber M; Henderson MJ
J Natl Cancer Inst; 2014 Jul; 106(7):. PubMed ID: 24957074
[TBL] [Abstract][Full Text] [Related]
24. Lymph node metastases as only qualifier for stage IV serous ovarian cancer confers longer survival than other sites of distant disease - a Swedish Gynecologic Cancer Group (SweGCG) study.
Hjerpe E; Staf C; Dahm-Kähler P; Stålberg K; Bjurberg M; Holmberg E; Borgfeldt C; Tholander B; Hellman K; Kjølhede P; Högberg T; Rosenberg P; Åvall-Lundqvist E
Acta Oncol; 2018 Mar; 57(3):331-337. PubMed ID: 29130381
[TBL] [Abstract][Full Text] [Related]
25. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
26. Predicting time to ovarian carcinoma recurrence using protein markers.
Yang JY; Yoshihara K; Tanaka K; Hatae M; Masuzaki H; Itamochi H; ; Takano M; Ushijima K; Tanyi JL; Coukos G; Lu Y; Mills GB; Verhaak RG
J Clin Invest; 2013 Sep; 123(9):3740-50. PubMed ID: 23945238
[TBL] [Abstract][Full Text] [Related]
27. Molecular alterations in indolent, aggressive and recurrent ovarian low-grade serous carcinoma.
McIntyre JB; Rambau PF; Chan A; Yap S; Morris D; Nelson GS; Köbel M
Histopathology; 2017 Feb; 70(3):347-358. PubMed ID: 27575406
[TBL] [Abstract][Full Text] [Related]
28. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study.
Ku FC; Wu RC; Yang LY; Tang YH; Chang WY; Yang JE; Wang CC; Jung SM; Lin CT; Chang TC; Chao A; Lai CH
J Formos Med Assoc; 2018 Feb; 117(2):117-125. PubMed ID: 28389144
[TBL] [Abstract][Full Text] [Related]
29. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
30. Preoperative CA-125 Value as a Predictive Factor for Postoperative Outcome in First Relapse of Platinum-sensitive Serous Ovarian Cancer.
Parashkevova A; Sehouli J; Richter R; Dimitrova D; Braicu EI; Muallem MZ
Anticancer Res; 2018 Aug; 38(8):4865-4870. PubMed ID: 30061261
[TBL] [Abstract][Full Text] [Related]
31. Proteases and their inhibitors as prognostic factors for high-grade serous ovarian cancer.
Trudel D; Avarvarei LM; Orain M; Turcotte S; Plante M; Grégoire J; Kappelhoff R; Labbé DP; Bachvarov D; Têtu B; Overall CM; Bairati I
Pathol Res Pract; 2019 Jun; 215(6):152369. PubMed ID: 30987833
[TBL] [Abstract][Full Text] [Related]
32. Overexpression of S100A14 in human serous ovarian carcinoma.
Qian J; Ding F; Luo A; Liu Z; Cui Z
Oncol Lett; 2016 Feb; 11(2):1113-1119. PubMed ID: 26893702
[TBL] [Abstract][Full Text] [Related]
33. Expression of Lysine-specific demethylase 1 in human epithelial ovarian cancer.
Chen C; Ge J; Lu Q; Ping G; Yang C; Fang X
J Ovarian Res; 2015 May; 8():28. PubMed ID: 25956476
[TBL] [Abstract][Full Text] [Related]
34. Lung resistance-related protein (LRP) expression in malignant ascitic cells as a prognostic marker for advanced ovarian serous carcinoma.
Kerr EH; Frederick PJ; Egger ME; Stockard CR; Sellers J; DellaManna D; Oelschlager DK; Amm HM; Eltoum IE; Straughn JM; Buchsbaum DJ; Grizzle WE; McNally LR
Ann Surg Oncol; 2013 Sep; 20(9):3059-65. PubMed ID: 23525731
[TBL] [Abstract][Full Text] [Related]
35. [Expression and significance of PD-1 and PD-L1 in the specimens of epithelial ovarian cancer].
Ju C; Gao JC; Zhang PX; Zhang KN; Yang S; Kang TJ; Zhao HZ; Qi WJ; Zhang QP; Kong FD; Guan HW; Shi H
Zhonghua Fu Chan Ke Za Zhi; 2020 Aug; 55(8):529-534. PubMed ID: 32854477
[No Abstract] [Full Text] [Related]
36. Prognostic significance of normal-sized ovary in advanced serous epithelial ovarian cancer.
Paik ES; Kim JH; Kim TJ; Lee JW; Kim BG; Bae DS; Choi CH
J Gynecol Oncol; 2018 Jan; 29(1):e13. PubMed ID: 29185271
[TBL] [Abstract][Full Text] [Related]
37. Long-term oncological outcomes of ovarian serous carcinomas with psammoma bodies: a novel insight into the molecular pathogenesis of ovarian epithelial carcinoma.
Motohara T; Tashiro H; Miyahara Y; Sakaguchi I; Ohtake H; Katabuchi H
Cancer Sci; 2010 Jun; 101(6):1550-6. PubMed ID: 20384630
[TBL] [Abstract][Full Text] [Related]
38. TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.
Brachova P; Mueting SR; Carlson MJ; Goodheart MJ; Button AM; Mott SL; Dai D; Thiel KW; Devor EJ; Leslie KK
Int J Oncol; 2015 Feb; 46(2):607-18. PubMed ID: 25385265
[TBL] [Abstract][Full Text] [Related]
39. Comparison of early-stage primary serous fallopian tube carcinomas and equivalent stage serous epithelial ovarian carcinomas.
Horng HC; Lai CR; Chang WH; Wen KC; Chen YJ; Juang CM; Yen MS; Wang PH
Taiwan J Obstet Gynecol; 2014 Dec; 53(4):547-51. PubMed ID: 25510699
[TBL] [Abstract][Full Text] [Related]
40. [The immunohistochemical features of ovarian serous adenocarcinoma cells, which determine a disease course and survival rates in patients].
Pozharissky KM; Raskin GA; Vinokurov VL; Yurkova LE; Mukhina MS
Arkh Patol; 2015; 77(1):38-40. PubMed ID: 25868367
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
